Protopic - Protopic is an immunosuppressant. It works by decreasing your body's immune system.
Protopic topical (for the skin) is used to treat severe atopic dermatitis (ezcema).
Protopic may also be used for purposes not listed in this medication guide.
Protopic is a macrolide antibiotic. It acts by reducing peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This inhibits both T-lymphocyte signal transduction and IL-2 transcription. Although this activity is similar to cyclosporine studies have shown that the incidence of acute rejection is reduced by Protopic use over cyclosporine. Protopic has also been shown to be effective in the topical treatment of eczema, particularly atopic eczema. It suppresses inflammation in a similar way to steroids, but is not as powerful. An important dermatological advantage of Protopic is that it can be used directly on the face; topical steroids cannot be used on the face, as they thin the skin dramatically there. On other parts of the body, topical steroid are generally a better treatment.
Indication: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Protopic is an immunosuppressant. It works by decreasing your body's immune system to help slow down the growth of atopic dermatitis (eczema) on your skin.
Protopic topical is used to treat severe atopic dermatitis when other medications have not worked well.
Protopic may also be used for purposes other than those listed here.
Adults (Protopic 0.03% and 0.1%) and Children 2-15 years (Protopic 0.03%): For short-term and intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis in whom the use of alternative, conventional therapies are deemed inadvisable because of potential risks or in the treatment of patients who are not adequately responsive to or are intolerant of alternative, conventional therapies.
Protopic, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2-15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non- immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis or when those treatments are not advisable.
Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.
Indications: atopic eczema
PO and IV Prophylaxis of organ rejection in patients receiving allogenic liver, kidney, or heart transplants. Used in conjunction with adrenal corticosteroids. Used in conjunction with azathioprine or mycophenolate mofetil in heart and kidney transplant patients. Topical As second-line therapy for the short-term and noncontinuous long-term treatment of moderate to severe atopic dermatitis. Unlabeled UsesPO and IV Prophylaxis of rejection for patients receiving bone marrow, pancreas, pancreatic island cell, and small bowel transplantation; treatment of autoimmune disease (ie, rheumatoid arthritis); prevention and treatment of acute graft-versus-host disease following hematopoietic stem cell transplantation; treatment of Crohn disease; treatment of pyoderma gangrenosum. Topical Treatment of vitiligo; cutaneous lupus erythematosis; facial, flexural, and intertriginous psoriasis; oral or genital lichen planus; pyoderma gangrenosum.
0.03%: For short- and long-term treatment of atopic dermatitis in adults and children ≥2 years. 0.1%: For short- and long-term treatment of atopic dermatitis in adults.